(Q36098699)

12 August 2017

1 reference

title

Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein (English)

1 reference

12 August 2017

1 reference

Honghui Zhou

1

1 reference

12 August 2017

publication date

1 May 2005

1 reference

The Journal of Clinical Pharmacology

12 August 2017

published in

1 reference

12 August 2017

volume

45

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

490-497

1 reference

12 August 2017

cites work

Human cytokine receptors

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Etanercept: a clinical review of current and emerging indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Etanercept in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Absence of a pharmacokinetic interaction between etanercept and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Clinical pharmacokinetics in heart failure. An updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Drug-patient interactions and their relevance in the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

The pharmacokinetics of etanercept in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Absence of a clinically relevant interaction between etanercept and digoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Pharmacokinetic considerations in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Rheumatoid arthritis. Pathophysiology and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

The cardiovascular response of normal humans to the administration of endotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273321

21 January 2018

Identifiers

DOI

10.1177/0091270004273321

1 reference

12 August 2017

1 reference